Pharma-Bio Serv, Inc. PBSV
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.25% | -5.49% | -8.08% | -5.35% | -14.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.25% | -5.49% | -8.08% | -5.35% | -14.75% |
| Cost of Revenue | 1.93% | -7.89% | -13.01% | -12.90% | -21.82% |
| Gross Profit | 6.14% | -0.04% | 4.21% | 15.66% | 6.19% |
| SG&A Expenses | -9.20% | -9.00% | -5.04% | -6.73% | -9.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.08% | -8.28% | -10.22% | -10.73% | -17.69% |
| Operating Income | 76.48% | 45.35% | 32.02% | 50.47% | 44.44% |
| Income Before Tax | 337.72% | 136.63% | 86.21% | 87.54% | 85.64% |
| Income Tax Expenses | 159.93% | 277.78% | -15.53% | -71.95% | -155.73% |
| Earnings from Continuing Operations | 398.46% | 132.51% | 84.73% | 87.08% | 89.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 398.46% | 132.51% | 84.73% | 87.08% | 89.97% |
| EBIT | 76.48% | 45.35% | 32.02% | 50.47% | 44.44% |
| EBITDA | 84.06% | 51.00% | 37.26% | 54.29% | 47.56% |
| EPS Basic | 405.56% | 132.93% | 84.79% | 87.32% | 90.19% |
| Normalized Basic EPS | 335.48% | 135.85% | 85.61% | 87.32% | 85.51% |
| EPS Diluted | 356.41% | 122.47% | 81.98% | 86.71% | 89.57% |
| Normalized Diluted EPS | 335.48% | 135.85% | 85.61% | 87.32% | 85.51% |
| Average Basic Shares Outstanding | -0.15% | -0.16% | -0.15% | -0.10% | -0.10% |
| Average Diluted Shares Outstanding | -0.15% | -0.14% | -0.13% | -0.11% | -0.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.33% | 4.07% | -5.54% | -6.73% | -8.96% |